Despite 40% of Americans living with obesity, access to GLP-1 medications is rapidly eroding. Nearly two-thirds of Americans with insurance are now in plans that either exclude all, or cover only one, new-generation obesity medication. In recent months, access to GLP-1 medications for weight management has been dealt a major setback, with insurers like Blue Cross Blue Shield announcing they will drop coverage for anti-obesity drugs in Massachusetts. Meanwhile, this past April, the Trump administration announced that Medicare and Medicaid will not be covering obesity medications, including GLP-1s.
.png)
.jpeg)
